GP Anastrozole has antitumor activity and inhibit the synthesis of estrogens. Anastrozole inhibits aromatase activity and prevents the conversion of androstenedione to estradiol. If it applied therapeutic dose estradiol level is reduced by 80%. Anastrozole drug effective in the tumor types of estrogen in postmenopausal women. Progestogenic, estrogenic, androgenic activity were observed.
Adjuvant treatment of postmenopausal breast cancer early gormonopolozhitelnogo.
Advanced breast cancer in postmenopausal women.
Adjuvant therapy gormonopolozhitelnogo early breast cancer in postmenopausal women after tamoxifen therapy for 2-3 years.
Side effects: dyspeptic phenomena, feeling hot flashes, vaginal dryness, thinning hair and alopecia, hypertension, thrombosis, myalgia, arthralgia, weakness, drowsiness, anxiety, sinusitis, rhinitis, bronchitis, anemia, leukopenia, increased levels of alkaline phosphatase, AST and ALT, allergic reaction.
Interaction: reduces the effectiveness of estrogen.